Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type...
12 KB (826 words) - 05:37, 26 March 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
86 KB (7,963 words) - 18:33, 12 September 2024
Daclizumab Inolimomab T-lymphocyte (Zolimomab aritox) Unsorted Alemtuzumab Anifrolumab Atorolimumab Begelomab Cedelizumab Emapalumab Fontolizumab Inebilizumab...
7 KB (299 words) - 13:45, 27 April 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
31 KB (2,632 words) - 22:56, 26 October 2024
L04AG08 Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab...
3 KB (367 words) - 15:37, 25 January 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
42 KB (3,486 words) - 00:32, 30 September 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
35 KB (3,965 words) - 16:19, 27 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
53 KB (4,975 words) - 03:43, 30 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
56 KB (5,566 words) - 04:53, 25 September 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
12 KB (705 words) - 02:49, 12 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
42 KB (3,798 words) - 21:12, 26 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
22 KB (2,320 words) - 13:06, 15 August 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (778 words) - 01:56, 27 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (836 words) - 03:56, 30 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
16 KB (1,284 words) - 04:32, 23 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
91 KB (9,320 words) - 23:17, 18 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
6 KB (352 words) - 17:16, 16 May 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
26 KB (2,203 words) - 06:19, 6 October 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
16 KB (1,412 words) - 06:19, 26 June 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
24 KB (1,917 words) - 17:27, 12 October 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
62 KB (7,065 words) - 05:17, 28 June 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
9 KB (457 words) - 05:12, 6 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
20 KB (1,378 words) - 23:33, 13 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
18 KB (1,573 words) - 05:19, 15 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
8 KB (967 words) - 18:35, 12 August 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
31 KB (3,428 words) - 18:05, 24 October 2024
pasudotox (anti-CD22) benralizumab (anti-IL-5R) tralokinumab (anti-IL-13) anifrolumab (anti-IFN-aR) nirsevimab (anti-RSV) MedImmune, Inc. v. Genentech, Inc...
9 KB (800 words) - 20:50, 24 October 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
46 KB (4,534 words) - 22:58, 20 August 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (799 words) - 13:28, 4 September 2024
(IFN-ω, IFNW1) Peginterferon alfa-2a Peginterferon alfa-2b Antibodies: Anifrolumab Faralimomab MEDI-545 Rontalizumab Sifalimumab Decoy receptors: Bifarcept...
33 KB (3,686 words) - 07:30, 20 May 2024